Thursday, 12 April 2012

MDA Funds Development of Utrophin 'Magnet' for DMD/BMD | Quest Magazine Online

MDA Funds Development of Utrophin 'Magnet' for DMD/BMD | Quest Magazine Online: MDA Funds Development of Utrophin 'Magnet' for DMD/BMD
MDA's $1 million grant will help fund the development of TVN-102, which attracts the muscle protein utrophin to the muscle-fiber membrane.

Article Highlights:
  • MDA funding will allow Tivorsan Pharmaceuticals to complete laboratory testing of TVN-102 and, if all goes well, to request permission from the FDA to begin human testing of the drug in 2012 or 2013.
  • TVN-102 (biglycan) acts like a magnet, attracting utrophin to the muscle-fiber membrane. Animal studies suggest that utrophin at the muscle-fiber membrane can partially compensate for a lack of the protein dystrophin at the membrane, helping to stabilize the membrane.

No comments:

Post a comment